Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

CYP2C19 point-of-care testing: where are we now and where should we go?

The Pharmacogenomics Journal volume 25, Article number: 16 (2025) Cite this article

Subjects

Access through your institution
Buy or subscribe

Genetic testing to inform on medication decisions has transformed from an expensive option only available in select academic settings to something that can be performed in most clinical practices by individuals trained to perform point-of-care (POC) tests. This isn’t referring to all genetic tests, but specifically those capable of providing results via POC devices, now able to identify variants for the highly polymorphic cytochrome P450 enzyme, CYP2C19.

The American Heart Association (AHA) has provided a scientific statement regarding CYP2C19 genetic testing specifically for P2Y12 inhibitor therapy [1]. The statement indicates that evidence is supportive of CYP2C19 genetic testing to guide P2Y12 therapy in the setting of acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI); however, incorporation into practice will require the implementation to provide (1) results quickly (2) clear actionable recommendations, readily discernable for a clinician to make a decision based on the information provided and (3) the results and recommendations are effectively integrated into the electronic health record [1].

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pereira NL, Cresci S, Angiolillo DJ, Batchelor W, Capers Q 4th, Cavallari LH, et al. CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association. Circulation. 2024;150:e129–e150.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Tomlinson E, Cooper C, Jones HE, Manzano CL, Palmer R, Carroll J, et al. Accuracy and technical characteristics of CYP2C19 point of care tests: a systematic review. Pharmacogenomics. 2024;25:407–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Carroll J, Lopez Manzano C, Tomlinson E, Sadek A, Cooper C, Jones HE, et al. Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model. Health Technol Assess. 2024;28:1–194.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Wright S, McDermott J, Sen D, Smith C, Newman W, Payne K. Development of a point-of-care genetic test for effective treatment of ischaemic stroke: an early model-based cost-effectiveness analysis. Wellcome Open Res. 2023;8:183.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Voicu V, Diehm N, Moarof I, Parejo S, Badiqué F, Burden A, et al. Antiplatelet therapy guided by CYP2C19 point-of-care pharmacogenetics plus multidimensional treatment decisions. Pharmacogenomics. 2024;25:5–19.

    Article  CAS  PubMed  Google Scholar 

  6. Gurbel PA, Bliden K, Sherwood M, Taheri H, Tehrani B, Akbari M, et al. Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratory. J Thromb Thrombolysis. 2024;57:566–75.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Levens AD, den Haan MC, Jukema JW, Heringa M, van den Hout WB, Moes DJAR, et al. Feasibility of community pharmacist-initiated and point-of-care CYP2C19 genotype-guided de-escalation of oral P2Y12 inhibitors. Genes. 2023;14:578.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Wang H, Yan C, Tong H, Ye X, Yuan X, Liu C, et al. Convenient two-step method constructed silicon-based microfluidic chip for fast CYP2C19 SNPs detection. RSC Adv. 2024;14:26007–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. National Institute for Health and Care Excellence (NICE). CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack. Guidance document. 2024. https://www.nice.org.uk/guidance/dg59/resources. Accessed October 19.

  10. Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA. 2020;324:761–71. https://doi.org/10.1001/jama.2020.12443.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Al-Rubaish AM, Al-Muhanna FA, Alshehri AM, Al-Mansori MA, Alali RA, Khalil RM, et al. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy. BMC Cardiovasc Disord. 2020;20:268.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Al-Rubaish AM, Al-Muhanna FA, Alshehri AM, Al-Mansori MA, Alali RA, Khalil RM, et al. Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients. Int J Cardiol. 2021;343:15–20.

    Article  PubMed  Google Scholar 

  13. Azzahhafi J, Broek WWAVD, Chan Pin Yin DRPP, Harmsze AM, van Schaik RHN, Ten Berg JM. The clinical implementation of CYP2C19 genotyping in patients with an acute coronary syndrome: insights from the FORCE-ACS registry. J Cardiovasc Pharmacol Ther. 2023;28:10742484231210704.

    Article  CAS  PubMed  Google Scholar 

  14. Tuteja S, Glick H, Matthai W, Nachamkin I, Nathan A, Monono K, et al. Prospective CYP2C19 genotyping to guide antiplatelet therapy following percutaneous coronary intervention: a pragmatic randomized clinical trial. Circ Genom Precis Med. 2020;13:e002640. https://doi.org/10.1161/CIRCGEN.119.002640.

    Article  CAS  PubMed  Google Scholar 

  15. Wan H, Han W, Wu Z, Lie Z, Li D, Su S. Whole blood dynamic platelet aggregation counting and 1-year clinical outcomes in patients with coronary heart diseases treated with clopidogrel. Platelets. 2021;32:968–74.

    Article  CAS  PubMed  Google Scholar 

  16. Hart MR, Garrison LP Jr, Doyle DL, Jarvik GP, Watkins J, Devine B. Projected cost-effectiveness for 2 gene-drug pairs using a multigene panel for patients undergoing percutaneous coronary intervention. Value Health. 2019;22:1231–9.

    Article  PubMed  Google Scholar 

  17. Huxley S, Moriarty J, Hlatky MA, Lennon R, Bailey K, Bell M, et al. Cost analysis of CYP2C19 genetic testing in percutaneous coronary intervention patients. Pharmacogenomics J. 2024;24:32.

    Article  CAS  PubMed  Google Scholar 

  18. Akhtar T, Bandyopadhyay D, Ghosh RK, Aronow WS, Lavie CJ, Yadav N. Advances in the pharmacogenomics of antiplatelet therapy. Am J Ther. 2020;27:e477–e484.

    Article  PubMed  Google Scholar 

  19. Xie X, Johnston SC, Wang A, Xu Q, Bath PM, Pan Y, et al. Association of CYP2C19 loss-of-function metabolizer status with stroke risk among chinese patients treated with ticagrelor-aspirin vs clopidogrel-aspirin: a prespecified secondary analysis of a randomized clinical trial. JAMA Netw Open. 2023;6:e2317037.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Mahajna M, Abu Fanne R, Berkovitch M, Tannous E, Vinker S, Green I, et al. Effect of CYP2C19 pharmacogenetic testing on predicting citalopram and escitalopram tolerability and efficacy: a retrospective, longitudinal cohort study. Biomedicines. 2023;11:3245.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Por ED, Selig DJ, Chin GC, DeLuca JP, Oliver TG, Livezey JR. Evaluation of pharmacogenomics testing of cytochrome P450 enzymes in the military health system from 2015 to 2020. Mil Med. 2021;187:1–8.

    Article  PubMed  Google Scholar 

  22. Desai M, Rachet B, Coleman MP, McKee M. Two countries divided by a common language: health systems in the UK and USA. J R Soc Med. 2010;103:283–7.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Ticagrelor. Lexi-Drugs. UpToDate Lexidrug. UpToDate Inc. 2024. https://online-lexi-com.dml.regis.edu. Accessed March 28.

  24. Galli M, Benenati S, Capodanno D, Franchi F, Rollini F, D’Amario D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet. 2021;397:1470–83.

    Article  PubMed  Google Scholar 

  25. Cohn I, Manshaei R, Liston E, Okello JBA, Khan R, Curtis MR, et al. Assessment of the implementation of pharmacogenomic testing in a pediatric tertiary care setting. JAMA Netw Open. 2021;4:e2110446.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Moliterno DJ, Smyth SS, Abdel-Latif A. CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary interventions: one size rarely fits all. JAMA. 2020;324:747–9.

    Article  CAS  PubMed  Google Scholar 

  27. Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, et al. Clopidogrel pharmacogenetics. Circ Cardiovasc Interv. 2019;12:e007811.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Yarlagadda A, Swift K, Chakraborty N, Hammamieh R, Abubakar A, Wilbur M, et al. Outpatient pharmacogenomic screenings to prevent addiction, overdose, and suicide. Innov Clin Neurosci. 2023;20:12–17.

    PubMed  PubMed Central  Google Scholar 

  29. Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharmacol Ther. 2023;114:51–68.

    Article  CAS  PubMed  Google Scholar 

  30. Narasimhalu K, Ang YK, Tan DSY, De Silva DA, Tan KB. Cost effectiveness of genotype-guided antiplatelet therapy in asian ischemic stroke patients: ticagrelor as an alternative to clopidogrel in patients with CYP2C19 loss of function mutations. Clin Drug Investig. 2020;40:1063–70.

    Article  CAS  PubMed  Google Scholar 

  31. Medical Expenditure Panel Survey (MEPS) 2013–22. Agency for healthcare research and quality (AHRQ). Rockville, MD: ClinCalc DrugStats Database. 2024.

  32. Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van ‘t Hof AWJ, van der Harst P, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381:1621–31.

    Article  CAS  PubMed  Google Scholar 

  33. Nguyen JQ, Crews KR, Moore BT, Kornegay NM, Baker DK, Hasan M, et al. Clinician adherence to pharmacogenomics prescribing recommendations in clinical decision support alerts. J Am Med Inform Assoc. 2022;30:132–8.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Meng X, Wang A, Zhang G, Niu S, Li W, Han S, et al. Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial. Stroke Vasc Neurol. 2021;6:274–9.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rueckert-Hartman College of Health Professions, Regis University, Denver, CO, USA

    Leticia A. Shea

Authors
  1. Leticia A. Shea
    View author publications

    Search author on:PubMed Google Scholar

Contributions

LAS was responsible for all aspects of the manuscript, including conception, analysis, and writing.

Corresponding author

Correspondence to Leticia A. Shea.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shea, L.A. CYP2C19 point-of-care testing: where are we now and where should we go?. Pharmacogenomics J 25, 16 (2025). https://doi.org/10.1038/s41397-025-00375-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41397-025-00375-0

Search

Advanced search

Quick links